Fetal Fentanyl Syndrome: Unveiling a New Syndrome Linked to Fentanyl Use During Pregnancy
Dr. Karen Gripp, MD, Chief of the Division of Medical Genetics at Nemours Children’s Health in Wilmington, has been at…
AI in Healthcare: Interview with Dekel Gelbman, CEO of FDNA
Updated April 9, 2023
AI Time Journal
“FDNA’s first NGP technology, DeepGestalt, is an AI-based module that analyzes facial photos of patients to highlight phenotypic similarity to known, but rare genetic disorders. This module was recently published in a peer-reviewed manuscript in Nature Medicine. It analyzes facial photos of patients to produce a list of syndromes that are found to have similar facial characteristics with accuracies of above 90%.”
The article explores the transformative impact of AI in healthcare, particularly in diagnosing rare genetic disorders. FDNA’s pioneering Face2Gene platform, which uses facial recognition and AI to detect phenotypic markers indicative of genetic syndromes. This innovative technology dramatically improves diagnostic accuracy and speed, empowering clinicians to make better-informed decisions. It emphasizes the potential of AI to revolutionize personalized medicine, enhancing patient care and outcomes by integrating advanced data analysis into healthcare practices.
Related articles
Continue reading
Interview with Dr. Giulia Pascolini: Unravelling the Genetic Underpinnings of Dermatological Anomalies
Dr Giulia Pascolini, an esteemed Italian M.D. and Ph.D., is currently responsible for the Genetic Counselling Service of the Istituto…
Spanish Coffin Siris Syndrome Association: Fighting for Health and Recognition
Founded in 2017, the Spanish Coffin Siris Syndrome Association is an organization dedicated to supporting families affected by this rare…